Business model and goals

Smaller and small biotech companies usually have a business model of out-licensing drug candidates to larger companies for further clinical development. This is usually done after clinical phase 2 but sometimes also in the preclinical phase. This is also DexTech’s business model. Such a license deal usually involves a one-time payment and thereafter compensation for achievement of development goals, so-called milestone compensation and future royalties on sales.